A. Buzdar

4.8k total citations · 1 hit paper
16 papers, 2.0k citations indexed

About

A. Buzdar is a scholar working on Oncology, Cancer Research and Genetics. According to data from OpenAlex, A. Buzdar has authored 16 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 11 papers in Cancer Research and 6 papers in Genetics. Recurrent topics in A. Buzdar's work include Breast Cancer Treatment Studies (10 papers), Estrogen and related hormone effects (6 papers) and Cancer Treatment and Pharmacology (6 papers). A. Buzdar is often cited by papers focused on Breast Cancer Treatment Studies (10 papers), Estrogen and related hormone effects (6 papers) and Cancer Treatment and Pharmacology (6 papers). A. Buzdar collaborates with scholars based in United States, United Kingdom and Switzerland. A. Buzdar's co-authors include Anthony Howell, J S Tobias, John Forbes, J. Houghton, G Hoctin-Boes, Jack Cuzick, Mitch Dowsett, Gershon Y. Locker, M Baum and J.F.R. Robertson and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

A. Buzdar

16 papers receiving 1.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer

2005 1.7k citations Anthony Howell, Jack Cuzick et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
A. Buzdar United States	7	1.2k	1.2k	846	356	253	16	2.0k
G Hoctin-Boes Netherlands	8	1.5k 1.2×	1.4k 1.2×	958 1.1×	392 1.1×	278 1.1×	12	2.4k
Monica Castiglione Switzerland	17	1.3k 1.0×	1.4k 1.2×	1.3k 1.6×	522 1.5×	258 1.0×	26	2.4k
JF Forbes Australia	12	1.9k 1.6×	1.7k 1.4×	1.4k 1.6×	471 1.3×	343 1.4×	26	3.0k
TJ Powles United Kingdom	19	1.2k 1.0×	991 0.8×	472 0.6×	200 0.6×	346 1.4×	39	1.9k
Gun Anker Norway	22	1.2k 1.0×	1.3k 1.1×	914 1.1×	396 1.1×	536 2.1×	38	2.4k
Aman U. Budzar United Kingdom	4	1.1k 0.9×	897 0.8×	801 0.9×	319 0.9×	227 0.9×	4	1.6k
Manuela Rabaglio Switzerland	22	779 0.6×	1.2k 1.0×	819 1.0×	589 1.7×	298 1.2×	83	2.0k
Alwynne Tidy United Kingdom	11	1.2k 1.0×	1.5k 1.3×	604 0.7×	284 0.8×	302 1.2×	17	2.2k
Claire Snowdon United Kingdom	8	651 0.5×	792 0.7×	454 0.5×	250 0.7×	184 0.7×	15	1.2k
M Baum United Kingdom	11	2.4k 1.9×	2.0k 1.7×	1.6k 1.9×	573 1.6×	455 1.8×	34	3.6k

Countries citing papers authored by A. Buzdar

Since Specialization

Citations

This map shows the geographic impact of A. Buzdar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. Buzdar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. Buzdar more than expected).

Fields of papers citing papers by A. Buzdar

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. Buzdar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. Buzdar. The network helps show where A. Buzdar may publish in the future.

Co-authorship network of co-authors of A. Buzdar

This figure shows the co-authorship network connecting the top 25 collaborators of A. Buzdar. A scholar is included among the top collaborators of A. Buzdar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. Buzdar. A. Buzdar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

O’Shaughnessy, Joyce, Hans‐Joachim Schmoll, Chris Twelves, et al.. (2011). Effect of dose modification on the efficacy of capecitabine: Data from six randomized, phase III trials in patients with colorectal or breast cancer.. Journal of Clinical Oncology. 29(15_suppl). 3627–3627. 2 indexed citations

Hsu, L., et al.. (2010). Abstract P5-10-02: Clinical Outcome of Two Sequences of Administering Paclitaxel (P) and Anthracyclines (A) as Primary Systemic Therapy (PST) and Adjuvant Chemotherapy (ACT) in Breast Cancer (BC) Patients: A Retrospective Analysis from the M. D. Anderson Cancer Center (MDACC). Cancer Research. 70(24_Supplement). P5–10. 5 indexed citations

Howell, Anthony, Jack Cuzick, M Baum, et al.. (2005). Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. The Lancet. 365(9453). 60–62. 1715 indexed citations breakdown →

Nabholtz, Jean‐Marc, J. Bonneterre, A. Buzdar, J.F.R. Robertson, & Beat Thürlimann. (2003). Anastrozole (Arimidex™) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results. European Journal of Cancer. 39(12). 1684–1689. 131 indexed citations

Huang, Emina H., E. A. Strom, Marsha D. McNeese, et al.. (2003). Radiation treatment improves local-regional control and survival in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy and mastectomy. International Journal of Radiation Oncology*Biology*Physics. 57(2). S238–S238. 4 indexed citations

Thames, Howard D., Erik H. Strøm, Marsha D. McNeese, et al.. (2003). Clinically-relevant pneumonitis is not increased in breast cancer patients treated with sequential paclitaxel and radiation. International Journal of Radiation Oncology*Biology*Physics. 57(2). S127–S128. 3 indexed citations

Boyeson, Michael G., et al.. (2001). Phase I study of the novel oral steroidal antiestrogenic agent TAS-108, ascending single dose, safety, tolerance, and pharmacokinetic parameters in healthy postmenopausal women. 69(3). 1 indexed citations

Buzdar, A.. (2000). An overview of the use of non-steroidal aromatase inhibitors in the treatment of breast cancer. European Journal of Cancer. 36. 82–84. 5 indexed citations

Robertson, J.F.R., et al.. (1999). Static disease on anastrozole provides similar benefit as objective response in patients with advanced breast cancer. Breast Cancer Research and Treatment. 58(2). 157–162. 32 indexed citations

10.

Buzdar, A.. (1998). The place of chemotherapy in the treatment of early breast cancer. British Journal of Cancer. 78(S4). 16–20. 16 indexed citations

11.

Hortobágyi, G. N. & A. Buzdar. (1995). Current status of adjuvant systemic therapy for primary breast cancer: progress and controversy. CA A Cancer Journal for Clinicians. 45(4). 199–226. 58 indexed citations

12.

Jonat, W., A. Buzdar, Anthony Howell, et al.. (1995). 351 Two randomised trials establishing efficacy and tolerability of arimidex (ZD1033) in the treatment of postmenopausal women with advanced breast cancer (PABC). European Journal of Cancer. 31. S76–S76. 3 indexed citations

13.

Valero, Vicente, R S Walters, R. Theriault, et al.. (1993). Phase II study of taxotere in refractory metastatic breast cancer (RMBC). European Journal of Cancer. 29. S83–S83. 14 indexed citations

14.

Hortobágyi, Gabriel N., Richard L. Theriault, D. Frye, et al.. (1990). Pirarubicin in Combination Chemotherapy for Metastatic Breast Cancer. American Journal of Clinical Oncology. 13. S54–S54. 4 indexed citations

15.

Buzdar, A., Terry L. Smith, Connie Marcus, G. N. Hortobagyi, & George R. Blumenschein. (1984). Significance of Drug Dose, Timing and Radiotherapy in Adjuvant Therapy of Breast Cancer. Recent results in cancer research. 96. 141–147. 3 indexed citations

16.

Gutterman, Jordan U., Yoon Sim Yap, & A. Buzdar. (1979). Leukocyte interferon (IF) induced tumor regression in patients (pts) with breast cancer and B cell neoplasms. 20. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact